3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Classical hematology
1
Conditions
Venous Thromboembolism
4
Venous Thrombosis
2
Thromboembolism
2
Lung Neoplasms
2
Pulmonary Embolism
1
Pancreatic Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Carboplatin
67
Cisplatin
57
Paclitaxel
42
Radiotherapy
35
Pemetrexed
34
Gemcitabine
31
Docetaxel
31
Etoposide
25
pembrolizumab
21
Vinorelbine
20
Erlotinib Hydrochloride
13
Magnetic Resonance Spectroscopy
12
Gefitinib
11
Specimen Handling
10
Radiosurgery
10
Drug Therapy
10
Bevacizumab
10
durvalumab
9
Nivolumab
9
Vinblastine
6
Topotecan
6
Surgical Procedures, Operative
6
Cyclophosphamide
6
atezolizumab
5
Standard of Care
5
Platinum
5
Immunoglobulin G
5
Ifosfamide
5
Disulfides
5
Dexamethasone
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Lung Neoplasms
×
Tinzaparin
×
Clear all
NCT03090880
2022-11-17
PROVE
Assistance Publique - Hôpitaux de Paris
Phase 3
Terminated
59 enrolled
NCT00475098
2016-09-02
TILT
Assistance Publique - Hôpitaux de Paris
Phase 3
Completed
553 enrolled